Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on August 13, 2018. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Boston, MA. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's stock listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance: the closing bid price of the Company's common stock remained below the minimum $1.00 per share requirement for 30 consecutive business days prior to the report date.
Material Changes
The primary material event is the receipt of a delisting notice from Nasdaq due to failure to satisfy the minimum bid price requirement under Listing Rule 5450(a)(1). This represents a significant compliance issue compared to the prior period where the stock presumably met listing standards.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted a 180-day compliance period, ending February 11, 2019, to regain compliance.
- Remediation Requirement: To cure the deficiency, the closing bid price must be at least $1.00 for a minimum of ten consecutive business days during the compliance period.
- Extension Possibility: If compliance is not met by the deadline, the Company may seek an extension if it meets all other listing standards, specifically the market value of publicly held shares.
- Delisting Risk: Failure to regain compliance by the end of the compliance period (including any extension) will result in written notice that securities are subject to delisting.
- Current Status: The notice has no immediate impact on trading; the stock continues to trade on the Nasdaq Global Market under the symbol "FLKS".
Investor Verification Checklist
- Verify the current closing bid price of Flex Pharma, Inc. (FLKS) to assess progress toward the $1.00 threshold.
- Monitor the company's public announcements for any stock split or reverse stock split proposals intended to adjust the share price.
- Confirm whether the company meets the market value of publicly held shares requirement, which is necessary to request a compliance extension.
- Review subsequent filings for updates on the 180-day compliance timeline and any correspondence with Nasdaq.